CHIP was created in 1998, to form a structure for the planning and execution of clinical, controlled trials, in Europe and elsewhere, related to therapies for infectious diseases in general and for HIV in particular.
CHIP organises or assists in organising the planning and execution of clinical controlled trials.
The EuroSIDA study is a prospective observational cohort study of more than 8.500 patients followed in 63 hospitals in 20 European Countries. The main objective of the study is to assess the impact of antiretroviral drugs on the outcome of the general population of HIV-infected patients living in Europe. The study is sponsored by the European Commission and by unrestricted grants from GlaxoSmithKline, Roche and Boehringer-Ingelheim. 11 cohorts across the world participate and 22.000 patients are expected to be enrolled during the year 2000. Coordination of CHIP initiated international randomised trials For these trials CHIP is acting as sponsor, organizer and monitor in all countries participating.